Aratana Therapeutics Inc (PETX) Stake Raised by Eagle Asset Management Inc.
Posted by Raelyn Donaldson on Mar 21st, 2016 // No Comments
Aratana Therapeutics logoEagle Asset Management Inc. raised its stake in Aratana Therapeutics Inc (NASDAQ
ETX) by 0.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 290,369 shares of the biopharmaceutical company’s stock after buying an additional 362 shares during the period. Eagle Asset Management Inc. owned about 0.83% of Aratana Therapeutics worth $1,620,000 at the end of the most recent reporting period.
Separately, Eagle Asset Management raised its stake in shares of Aratana Therapeutics by 188.4% in the third quarter. Eagle Asset Management now owns 580,014 shares of the biopharmaceutical company’s stock valued at $4,906,000 after buying an additional 378,920 shares in the last quarter.
Shares of Aratana Therapeutics Inc (NASDAQ ETX) traded up 18.40% during trading on Monday, hitting $5.34. The company had a trading volume of 621,314 shares. The stock’s 50-day moving average price is $3.56 and its 200 day moving average price is $6.91. The company’s market capitalization is $186.93 million. Aratana Therapeutics Inc has a 52 week low of $2.56 and a 52 week high of $19.99.
Aratana Therapeutics (NASDAQ ETX) last issued its earnings results on Monday, March 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.04. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.21 million. The firm’s revenue for the quarter was down 76.0% compared to the same quarter last year. During the same period last year, the business posted ($0.30) EPS. On average, equities research analysts forecast that Aratana Therapeutics Inc will post ($1.36) earnings per share for the current year.
PETX has been the subject of several research reports. Stifel Nicolaus cut their target price on Aratana Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, March 16th. Jefferies Group reiterated a “buy” rating and issued a $12.00 price objective (down previously from $18.00) on shares of Aratana Therapeutics in a research report on Wednesday, January 20th. Barclays reiterated a “buy” rating on shares of Aratana Therapeutics in a research report on Wednesday, December 2nd. Zacks Investment Research downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Craig Hallum lowered their price objective on Aratana Therapeutics from $11.00 to $7.00 and set a “hold” rating for the company in a research report on Wednesday, March 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. Aratana Therapeutics has an average rating of “Buy” and a consensus target price of $12.81.
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats.
12 Month Chart for NASDAQ ETX
Posted by Raelyn Donaldson on Mar 21st, 2016 // No Comments
Aratana Therapeutics logoEagle Asset Management Inc. raised its stake in Aratana Therapeutics Inc (NASDAQ
ETX) by 0.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 290,369 shares of the biopharmaceutical company’s stock after buying an additional 362 shares during the period. Eagle Asset Management Inc. owned about 0.83% of Aratana Therapeutics worth $1,620,000 at the end of the most recent reporting period. Separately, Eagle Asset Management raised its stake in shares of Aratana Therapeutics by 188.4% in the third quarter. Eagle Asset Management now owns 580,014 shares of the biopharmaceutical company’s stock valued at $4,906,000 after buying an additional 378,920 shares in the last quarter.
Shares of Aratana Therapeutics Inc (NASDAQ
ETX) traded up 18.40% during trading on Monday, hitting $5.34. The company had a trading volume of 621,314 shares. The stock’s 50-day moving average price is $3.56 and its 200 day moving average price is $6.91. The company’s market capitalization is $186.93 million. Aratana Therapeutics Inc has a 52 week low of $2.56 and a 52 week high of $19.99. Aratana Therapeutics (NASDAQ
ETX) last issued its earnings results on Monday, March 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.04. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.21 million. The firm’s revenue for the quarter was down 76.0% compared to the same quarter last year. During the same period last year, the business posted ($0.30) EPS. On average, equities research analysts forecast that Aratana Therapeutics Inc will post ($1.36) earnings per share for the current year. PETX has been the subject of several research reports. Stifel Nicolaus cut their target price on Aratana Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, March 16th. Jefferies Group reiterated a “buy” rating and issued a $12.00 price objective (down previously from $18.00) on shares of Aratana Therapeutics in a research report on Wednesday, January 20th. Barclays reiterated a “buy” rating on shares of Aratana Therapeutics in a research report on Wednesday, December 2nd. Zacks Investment Research downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Craig Hallum lowered their price objective on Aratana Therapeutics from $11.00 to $7.00 and set a “hold” rating for the company in a research report on Wednesday, March 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. Aratana Therapeutics has an average rating of “Buy” and a consensus target price of $12.81.
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats.
12 Month Chart for NASDAQ
ETX
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
